In this episode, Dr. Gary  Sherman addresses many of the most important questions with Dr. Hayanga, in this most crucial time of the COVID-19 pandemic resurgence. 
Some of these questions are :
- Why are the people seriously affected by the COVID-19 Variant younger than the previous population of affected patients? 
- What is ECMO and why does it play such a critical role in the therapy for those most seriously affected by the virus? 
- What are the factors that will allow the pandemic to subside so that we can feel a sense of "normalcy" again?
- Why are some factions of people more drastically affected by the virus than others?
- What is the most important "medicine" needed to mitigate the pandemic?
- What is the role of Artificial Intelligence in helping to get a foothold on the COVID-19 pandemic resurgence? 
- How will the immunosuppressed portion of the population fare in the face of the pandemic and how will the pandemic affect organ donation? 

Dr. Hayanga is a Professor in Cardiothoracic Surgery at West Virginia University School of Medicine. He is the Director of the West Virginia University Heart & Vascular Institute ECMO Program. Dr. Hayanga is Board Certified in Cardiothoracic Surgery, General Surgery and Surgical Critical Care. He completed his general surgical training at Johns Hopkins University and the University of Michigan - followed by cardiothoracic and transplant training at the University of Washington and the University of Pittsburgh, respectively. Dr. Hayanga has served as an Alfred Sommer Scholar during his master’s in public health training at the Johns Hopkins School of Public Health. He is also a 2008 World Health Organization (WHO) Patient Safety Scholar, a Department of Health and Human Services (HHS) Fellow and Senior Medical Advisor to the Deputy Secretary in Washington, D.C.  Dr. Hayanga holds a master’s degree in Healthcare Leadership from Brown University and a certificate in Artificial Intelligence and Business Strategy from MIT.  He is an expert - Health - Policy panelist with RAND Corporation, elected member of American Association of Thoracic Surgery (AATS), and editorial board member for Journal of Thoracic and Cardiovascular Surgery, the Journal of Heart & Lung Transplantation, and LUNG.  He has authored over 150 peer-reviewed papers and his clinical work and research focus on ECMO, transplantation, and application of data analytics in the prevention, diagnosis, and mitigation of end-stage cardiopulmonary disease. He is a fellow of the American College of Surgeons, the Royal College of Surgeons, and the American College of Chest Physicians. 

DO NOT MISS this episode of great importance!! 
Dr. Hayanga sheds light on our most pressing questions during this uptick of variant-related illness throughout parts of our country. 

More about Dr. Jeremiah Hayanga's illustrious  background may be found at:  https://www.doximity.com/pub/jeremiah-hayanga-md










e